KR20080106950A - 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제 - Google Patents
정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제 Download PDFInfo
- Publication number
- KR20080106950A KR20080106950A KR1020087023804A KR20087023804A KR20080106950A KR 20080106950 A KR20080106950 A KR 20080106950A KR 1020087023804 A KR1020087023804 A KR 1020087023804A KR 20087023804 A KR20087023804 A KR 20087023804A KR 20080106950 A KR20080106950 A KR 20080106950A
- Authority
- KR
- South Korea
- Prior art keywords
- leu
- thr
- ser
- artificial sequence
- gln
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2006/012601 WO2006105527A2 (en) | 2005-03-31 | 2006-03-31 | Amylin and amylin agonists for treating psychiatric diseases and disorders |
| USPCT/US2006/012601 | 2006-03-31 | ||
| PCT/US2006/038919 WO2007114838A1 (en) | 2006-03-31 | 2006-10-04 | Amylin and amylin agonists for treating psychiatric diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080106950A true KR20080106950A (ko) | 2008-12-09 |
Family
ID=39876652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087023804A Ceased KR20080106950A (ko) | 2006-03-31 | 2006-10-04 | 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2010208A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009538824A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080106950A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006341375B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2647568A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008012666A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007114838A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100204107A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of urodilatin as a therapeutic agent |
| WO2009043469A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of pneumadin as a therapeutic agent |
| JP2011525895A (ja) * | 2008-06-25 | 2011-09-29 | ノボ・ノルデイスク・エー/エス | アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド |
| JP2013511287A (ja) | 2009-11-23 | 2013-04-04 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | ポリペプチド・コンジュゲート |
| BR112013007442A2 (pt) | 2010-09-28 | 2019-09-24 | Amylin Pharmaceuticals Llc | polipeptídeos construídos tendo duração de ação realçada |
| MX349054B (es) | 2010-09-28 | 2017-07-07 | Aegerion Pharmaceuticals Inc | Leptinas altamente solubles. |
| WO2012162547A2 (en) | 2011-05-25 | 2012-11-29 | Amylin Pharmaceuticals, Inc. | Long duration dual hormone conjugates |
| WO2012160212A1 (en) | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
| DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| JP7505713B2 (ja) | 2019-02-22 | 2024-06-25 | ロヨラ メリーマウント ユニバーシティ | アミロイドペプチドバリアント |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| HU222249B1 (hu) * | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| ES2108122T3 (es) * | 1991-05-24 | 1997-12-16 | Amylin Pharmaceuticals Inc | Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas. |
| EP1750752A2 (en) * | 2003-11-20 | 2007-02-14 | Neuronova AB | Compounds and methods for increasing neurogenesis |
| US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| KR20080003849A (ko) * | 2005-03-31 | 2008-01-08 | 아밀린 파마슈티칼스, 인크. | 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법 |
-
2006
- 2006-10-04 WO PCT/US2006/038919 patent/WO2007114838A1/en not_active Ceased
- 2006-10-04 KR KR1020087023804A patent/KR20080106950A/ko not_active Ceased
- 2006-10-04 JP JP2009502755A patent/JP2009538824A/ja active Pending
- 2006-10-04 CA CA002647568A patent/CA2647568A1/en not_active Abandoned
- 2006-10-04 EP EP06816288A patent/EP2010208A1/en not_active Withdrawn
- 2006-10-04 MX MX2008012666A patent/MX2008012666A/es active IP Right Grant
- 2006-10-04 AU AU2006341375A patent/AU2006341375B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2647568A1 (en) | 2007-10-11 |
| WO2007114838A1 (en) | 2007-10-11 |
| AU2006341375A1 (en) | 2007-10-11 |
| MX2008012666A (es) | 2008-10-13 |
| EP2010208A1 (en) | 2009-01-07 |
| AU2006341375B2 (en) | 2013-03-21 |
| JP2009538824A (ja) | 2009-11-12 |
| AU2006341375A2 (en) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101383493B1 (ko) | 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및아밀린 효능제 | |
| US7910548B2 (en) | Methods for treating obesity | |
| US20050197287A1 (en) | Methods for affecting body composition | |
| CN102753192A (zh) | 治疗代谢综合征的药物组合物 | |
| AU2006341375B2 (en) | Amylin and amylin agonists for treating psychiatric diseases and disorders | |
| EP0964695B1 (en) | Methods and compositions for treating pain | |
| US20130035294A1 (en) | Neuromedin and FN-38 Peptides for Psychotic Diseases | |
| WO2005021026A2 (en) | Methods for treating or ameliorating ghrelin-associated diseases and disorders | |
| US20090181890A1 (en) | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders | |
| CN101208098A (zh) | 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂 | |
| WO2005074916A1 (en) | Methods and compositions for the treatment of lipodystrophy | |
| MXPA06007761A (en) | Methods and compositions for the treatment of lipodystrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20080929 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20110930 Comment text: Request for Examination of Application |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20130218 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130516 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20131025 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130516 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |